Prosecution Insights
Last updated: April 19, 2026

Examiner: BORALSKY, LUKE ALAN

Tech Center 1600 • Art Units: 1624 1625 1657

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
19
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
8.9%
§102 Novelty
20.0%
§103 Obviousness
53.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18554778 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY Non-Final OA Novartis AG
18539931 AGENT FOR ANTI-AGING OR FOR CELLULAR REJUVENATION Non-Final OA TOHOKU UNIVERSITY
18272919 COMBINATION OF INTRACELLULAR AND EXTRACELLULAR PHOTOSENSITIZERS FOR TREATMENT OF BACTERIAL INFECTION Non-Final OA Vanderbilt University
18365919 SARS-COV2 MAIN PROTEASE INHIBITORS Non-Final OA Gilead Sciences, Inc.
18335415 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS Non-Final OA Intervet Inc.
18572862 TRK KINASE INHIBITOR COMPOUND AND USE THEREOF Non-Final OA HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD.
18284943 DIAZEPANONE-FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Non-Final OA Blueprint Medicines Corporation
18572432 APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND Non-Final OA Betta Pharmaceuticals Co., Ltd
18284654 TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE Non-Final OA Shanghai Hengrui Pharmaceutical Co., Ltd.
18535503 SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF Non-Final OA Crinetics Pharmaceuticals, Inc.
18561553 COMPOUND USED AS BCR-ABL INHIBITOR Non-Final OA CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
18557191 (HETERO)ARYLAMIDE COMPOUND AND PEST CONTROL AGENT Non-Final OA Nippon Soda Co., Ltd.
18556775 PREPARATION METHOD OF L-NICOTINE Non-Final OA WUHAN QR PHARMACEUTICALS CO., LTD.
18369853 COMBINATION THERAPY WITH IMMUNOTHERAPEUTIC AGENT FOR CANCER Non-Final OA Gongwin Biopharm Co., Ltd
18466730 PROCESS FOR THE PREPARATION OF IMIDAZOBENZODIAZEPINES Non-Final OA ODH IP Corp.
18157686 THERAPEUTIC AGENTS TARGETING GPR35 Non-Final OA PROMETHEUS BIOSCIENCES, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month